<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515878</url>
  </required_header>
  <id_info>
    <org_study_id>2019</org_study_id>
    <nct_id>NCT01515878</nct_id>
  </id_info>
  <brief_title>Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS</brief_title>
  <acronym>HERACLES</acronym>
  <official_title>Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that a consistent use of the Hemocontrol TM biofeedback function improves&#xD;
      long-term cardiovascular outcome, mediated by reduced hypertension due to fluid overload and&#xD;
      by reduced incidence of intradialytic hypotensive episodes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>The primary objective will be assessed by the incidence rate of Fatal and not fatal cardiovascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>36 months</time_frame>
    <description>Number of hospital admissions evaluated as annual hospitalization rate related to: Non fatal myocardial infarction, New-onset angina, Non fatal stroke, Congestive heart failure, Transient ischemic attack, Pulmonary oedema&#xD;
Length of stay during hospitalization;&#xD;
Number of extra dialysis or prolonged dialysis due to fluid overload.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>36 months</time_frame>
    <description>Blood pressure control:&#xD;
Predialysis blood pressure measurements&#xD;
Home blood pressure self assessment&#xD;
Antihypertensive therapy changes&#xD;
Proportion of patients achieving adequate blood pressure control&#xD;
Intradialytic acute hypotension:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and dialysis tolerance evaluated with questionnaire.</measure>
    <time_frame>36 months</time_frame>
    <description>Questions of the KDQOL36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry weight management</measure>
    <time_frame>36 months</time_frame>
    <description>Optional when available at site: Hydration status estimated by Cardiothoracic index or BNP or BIA at baseline and each 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Kidney Failure Chronic</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Dialysis with BVT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysis using the BVT monitor biofeedback called Hemocontrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional dialysis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional dialysis without blood volume tracking or similar therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemocontrol</intervention_name>
    <description>Blood Volume Tracking system using biofeedback</description>
    <arm_group_label>Dialysis with BVT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age more than 65 years old&#xD;
&#xD;
          2. Arterial Hypertension: predialysis SBP &gt;140 mmHg and/or DBP &gt;90 mmHg in at least 50%&#xD;
             over the previous month dialysis sessions or receiving at least one antihypertensive&#xD;
             pharmacological drug including diuretics, disregarded blood pressure value&#xD;
&#xD;
          3. On a three times per week hemodialysis schedule&#xD;
&#xD;
          4. Time on hemodialysis less than 6 months&#xD;
&#xD;
          5. Able to measure their blood pressure at home (by themselves or with the aid of the&#xD;
             care giver)&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active neoplastic disease&#xD;
&#xD;
          2. Mental illness&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Single needle treatment&#xD;
&#xD;
          5. Inability, as judged by the investigator, to follow or understand the protocol&#xD;
             instructions&#xD;
&#xD;
          6. Blood flow rate less than 200 mL/min&#xD;
&#xD;
          7. Patients who at the time of recruitment need clinical indication for special renal&#xD;
             replacement therapies and/or on treatment with one of the following modalities: HDF or&#xD;
             similar diffusive-convective therapies, treatment time &gt;5h, blood temperature control,&#xD;
             isolated UF profiling of Na/UFR&#xD;
&#xD;
          8. Patients with a life expectancy shorter than 6 months&#xD;
&#xD;
          9. Patients in a list for transplant within the next 6 months&#xD;
&#xD;
         10. Predialysis Hemoglobin level greater than 13.5 g/dl&#xD;
&#xD;
         11. History of major cardiovascular events during run in period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Mac Rae, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Calgary hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hafedh Fessi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP Tenon, Paris France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Buades, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Majorca hospital, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Mancini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AOSP, Bologna Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Santoro, Pf</last_name>
    <role>Study Chair</role>
    <affiliation>AOSP, Bologna Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Santoro, Pf</last_name>
    <phone>+39 051 6362 430</phone>
    <email>antonio.santoro@aosp.bo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helena Mancini, MD</last_name>
    <email>elena.mancini@aosp.bo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Regional hospital</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Mac Rae, MD</last_name>
      <email>jennifer.macrae@calgaryhealthregion.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer Mac Rae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Santoro, Pf</last_name>
      <phone>+39 051 63 62 430</phone>
      <email>antonio.santoro@aosp.bo.it</email>
    </contact>
    <contact_backup>
      <last_name>Elena Mancini, MD</last_name>
      <email>elena.mancini@aosp.bo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Santoro, Pf</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Mancini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Antonio Santoro</investigator_full_name>
    <investigator_title>Professor, MD, Chief of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

